News | October 31, 2025
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
Subscribe To Our Newsletter & Stay Updated
